Pfizer and Starna Therapeutics Deal Worth $2.6 Billion Targets Autoimmune Therapies

Pfizer and Starna Therapeutics Deal

Follow Us:

November 19, 2026

Overview :

Pfizer has entered a $2.6 billion licensing agreement with China’s Starna Therapeutics to develop three experimental cell therapies for autoimmune diseases. The Pfizer and Starna Therapeutics deal gives Pfizer exclusive rights outside Greater China to develop, manufacture, and commercialize three early-stage in vivo chimeric antigen receptor T-cell (CAR-T) programs.

The Starna Therapeutics licensing agreement includes a $330 million upfront payment, potential milestone payments of up to $2.3 billion, and royalties on sales of approved products. The partnership also marks Pfizer’s entry into the emerging in vivo CAR-T field, expanding its research into next-generation cell therapies.

Details of Pfizer-Starna Therapeutics Licensing Agreement

Under the Pfizer and Starna Therapeutics deal, the companies have established the following development arrangements:

  • Upfront payment: Pfizer will pay Starna $330 million.
  • Milestone payments: Starna could receive up to $2.3 billion based on specified development and commercial milestones.
  • Royalties: Starna will receive royalties on net sales of approved products.
  • Development rights: Pfizer obtains exclusive rights to three autoimmune disease programs outside Greater China.
  • Manufacturing: Pfizer plans to manufacture finished drug products for initial clinical trials at its facilities in the United States.

Pfizer will lead clinical development and control commercialization of the experimental cell therapies outside Greater China. It also holds options to expand its licensing territory into Greater China.

Beyond the three programs, Pfizer gains rights to use Starna’s proprietary in vivo CAR-T technology in inflammation, immunology and oncology. Pfizer and Starna Therapeutics will also explore additional compounds through a separate research collaboration.

Vivo CAR-T Technology Transforms Autoimmune Disease Treatment

The Pfizer Starna Therapeutics partnership focuses on in vivo CAR-T technology, an emerging approach that aims to modify immune cells directly inside the patient’s body.

Starna Therapeutics, founded in 2021, develops RNA medicines and in vivo cell therapies. Its broader pipeline also includes therapeutic cancer vaccine candidates and a respiratory syncytial virus (RSV) vaccine.

CAR-T therapy uses genetically modified T cells, a type of immune cell, to recognize and attack specific targets. Conventional CAR-T treatment requires doctors to collect a patient’s T cells, modify them in a laboratory, and return them to the body.

In contrast, in vivo CAR-T technology aims to deliver the genetic instructions directly into the body, potentially simplifying this complex process.

Starna’s proprietary targeted lipid nanoparticle (LNP) delivery platform and RNA technology support its approach. LNPs are tiny particles designed to transport therapeutic materials into cells.

Researchers are exploring whether Vivo CAR-T technology could help address autoimmune diseases by targeting harmful immune cells and potentially resetting immune system activity.

Pfizer Expands Cell Therapy Pipeline & Immunology Research

The Pfizer and Starna Therapeutics deal strengthens Pfizer’s cell therapy pipeline and expands its inflammation and immunology research strategy.

Pfizer already has experience developing and manufacturing RNA-based medicines, including its COVID-19 vaccine Comirnaty. However, the Starna agreement represents the pharmaceutical company’s first move specifically into in vivo CAR-T therapies.

Pfizer’s Chief Inflammation and Immunology Officer, Michael Vincent, M.D., Ph.D., said in the official announcement, “In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases.” He added that the approach could benefit patients whose needs remain unmet by existing treatment options.

Pfizer and Starna Therapeutics Deal For Future Research

The three Starna Therapeutics CAR-T programs remain at the pre-investigational new drug (pre-IND) stage, meaning they have not yet entered human clinical trials.

With the Pfizer and Starna Therapeutics deal, the companies must complete further research and evaluate the therapies’ safety and effectiveness before they can advance through clinical development.

pharmaceutical industry’s interest in in vivo cell therapies for conditions beyond cancer are also growing. Companies are increasingly exploring CAR-T approaches for autoimmune disorders, including lupus and multiple sclerosis.

However, these potential applications remain under investigation. Clinical safety, effective delivery, and regulatory requirements will influence their development.

Whether the three experimental programs can deliver new autoimmune disease treatment options will depend on their progress through preclinical research and future clinical trials.

Sanskruti Jadhav is an SEO content writer at Global Healthcare Magazine. She specializes in creating healthcare and business content through blogs, news articles, and digital content for diverse audiences. A graduate in Journalism and Mass Communication, she aims to deliver authentic and impactful information through her writing.